English
简体中文
Total: £ 56.28
Published Date: 2022-07-28 | Pages: 103 | Tables: 149 | Pharma & Healthcare
TNF inhibitors are drugs that help stop inflammation. They're used to treat diseases like rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis (UC), and Crohn's disease.They're also called TNF blockers, biologic therapies, or anti-TNF drugs.
Due to the COVID-19 pandemic, the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Remicade accounting for % of the Tumor Necrosis Factor (TNF) Inhibitor Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Online Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Tumor Necrosis Factor (TNF) Inhibitor Drugs include Takeda Pharmaceuticals, Amgen, AbbVie, Pfizer, Novartis, Johnson and Johnson, UCB, Merck and Abbott Laboratories, etc. In terms of revenue, the global 3 largest players have a % market share of Tumor Necrosis Factor (TNF) Inhibitor Drugs in 2021.
This report focuses on Tumor Necrosis Factor (TNF) Inhibitor Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Tumor Necrosis Factor (TNF) Inhibitor Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Remicade
Humira
Cimzia
Simponi
Others
Segment by Application
Online Pharmacies
Specialty Pharmacies
Hospital Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Takeda Pharmaceuticals
Amgen
AbbVie
Pfizer
Novartis
Johnson and Johnson
UCB
Merck
Abbott Laboratories
Biogen
Gilead Sciences
Thermo Fisher Scientific
Bristol-Myers Squibb
Astellas Pharma
AstraZeneca
Eli Lilly and Company
Roche
Sanofi
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Overview
1.1 Product Overview and Scope of Tumor Necrosis Factor (TNF) Inhibitor Drugs
1.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Type
1.2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Remicade
1.2.3 Humira
1.2.4 Cimzia
1.2.5 Simponi
1.2.6 Others
1.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Application
1.3.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Online Pharmacies
1.3.3 Specialty Pharmacies
1.3.4 Hospital Pharmacies
1.4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size Estimates and Forecasts
1.4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue 2017-2028
1.4.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales 2017-2028
1.4.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Competition by Manufacturers
2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Tumor Necrosis Factor (TNF) Inhibitor Drugs Manufacturing Sites, Area Served, Product Type
2.5 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Competitive Situation and Trends
2.5.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Tumor Necrosis Factor (TNF) Inhibitor Drugs Players Market Share by Revenue
2.5.3 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Retrospective Market Scenario by Region
3.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Facts & Figures by Country
3.3.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country
3.3.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Facts & Figures by Country
3.4.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country
3.4.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Region
3.5.2 Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Facts & Figures by Country
3.6.1 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country
3.6.2 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country
3.7.2 Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Analysis by Type
4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2022)
4.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Price by Type (2017-2022)
5 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Analysis by Application
5.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2022)
5.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Takeda Pharmaceuticals Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Amgen Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 AbbVie Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Novartis Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Johnson and Johnson
6.6.1 Johnson and Johnson Corporation Information
6.6.2 Johnson and Johnson Description and Business Overview
6.6.3 Johnson and Johnson Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Johnson and Johnson Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.6.5 Johnson and Johnson Recent Developments/Updates
6.7 UCB
6.6.1 UCB Corporation Information
6.6.2 UCB Description and Business Overview
6.6.3 UCB Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 UCB Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.7.5 UCB Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Merck Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 Abbott Laboratories
6.9.1 Abbott Laboratories Corporation Information
6.9.2 Abbott Laboratories Description and Business Overview
6.9.3 Abbott Laboratories Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Abbott Laboratories Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.9.5 Abbott Laboratories Recent Developments/Updates
6.10 Biogen
6.10.1 Biogen Corporation Information
6.10.2 Biogen Description and Business Overview
6.10.3 Biogen Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Biogen Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.10.5 Biogen Recent Developments/Updates
6.11 Gilead Sciences
6.11.1 Gilead Sciences Corporation Information
6.11.2 Gilead Sciences Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.11.3 Gilead Sciences Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Gilead Sciences Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.11.5 Gilead Sciences Recent Developments/Updates
6.12 Thermo Fisher Scientific
6.12.1 Thermo Fisher Scientific Corporation Information
6.12.2 Thermo Fisher Scientific Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.12.3 Thermo Fisher Scientific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Thermo Fisher Scientific Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.12.5 Thermo Fisher Scientific Recent Developments/Updates
6.13 Bristol-Myers Squibb
6.13.1 Bristol-Myers Squibb Corporation Information
6.13.2 Bristol-Myers Squibb Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.13.3 Bristol-Myers Squibb Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Bristol-Myers Squibb Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.13.5 Bristol-Myers Squibb Recent Developments/Updates
6.14 Astellas Pharma
6.14.1 Astellas Pharma Corporation Information
6.14.2 Astellas Pharma Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.14.3 Astellas Pharma Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Astellas Pharma Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.14.5 Astellas Pharma Recent Developments/Updates
6.15 AstraZeneca
6.15.1 AstraZeneca Corporation Information
6.15.2 AstraZeneca Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.15.3 AstraZeneca Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.15.4 AstraZeneca Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.15.5 AstraZeneca Recent Developments/Updates
6.16 Eli Lilly and Company
6.16.1 Eli Lilly and Company Corporation Information
6.16.2 Eli Lilly and Company Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.16.3 Eli Lilly and Company Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Eli Lilly and Company Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.16.5 Eli Lilly and Company Recent Developments/Updates
6.17 Roche
6.17.1 Roche Corporation Information
6.17.2 Roche Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.17.3 Roche Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Roche Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.17.5 Roche Recent Developments/Updates
6.18 Sanofi
6.18.1 Sanofi Corporation Information
6.18.2 Sanofi Tumor Necrosis Factor (TNF) Inhibitor Drugs Description and Business Overview
6.18.3 Sanofi Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Sanofi Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
6.18.5 Sanofi Recent Developments/Updates
7 Tumor Necrosis Factor (TNF) Inhibitor Drugs Manufacturing Cost Analysis
7.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Tumor Necrosis Factor (TNF) Inhibitor Drugs
7.4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Distributors List
8.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Customers
9 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Dynamics
9.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Trends
9.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers
9.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Challenges
9.4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints
10 Global Market Forecast
10.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Type (2023-2028)
10.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Application (2023-2028)
10.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Growth Rate Comparison by Type (2022-2028) & (MT) & (US$ Million)
Table 2. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Growth Rate Comparison by Application (2022-2028) & (MT) & (US$ Million)
Table 3. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Competitive Situation by Manufacturers in 2021
Table 5. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT) of Key Manufacturers (2017-2022)
Table 6. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Tumor Necrosis Factor (TNF) Inhibitor Drugs Average Price (USD/MT) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Tumor Necrosis Factor (TNF) Inhibitor Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Region (2017-2022) & (MT)
Table 16. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Region (2017-2022)
Table 17. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region (2017-2022)
Table 19. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country (2017-2022) & (MT)
Table 20. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 21. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 23. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country (2017-2022) & (MT)
Table 24. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 25. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Region (2017-2022) & (MT)
Table 28. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region (2017-2022)
Table 31. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country (2017-2022) & (MT)
Table 32. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 33. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Country (2017-2022) & (MT)
Table 36. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 39. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales by Type (2017-2022) & (MT)
Table 40. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2022)
Table 41. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Type (2017-2022)
Table 43. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Price by Type (2017-2022) & (USD/MT)
Table 44. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT) by Application (2017-2022)
Table 45. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2022)
Table 46. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Application (2017-2022)
Table 48. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Price by Application (2017-2022) & (USD/MT)
Table 49. Takeda Pharmaceuticals Corporation Information
Table 50. Takeda Pharmaceuticals Description and Business Overview
Table 51. Takeda Pharmaceuticals Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 52. Takeda Pharmaceuticals Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 53. Takeda Pharmaceuticals Recent Developments/Updates
Table 54. Amgen Corporation Information
Table 55. Amgen Description and Business Overview
Table 56. Amgen Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 57. Amgen Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 58. Amgen Recent Developments/Updates
Table 59. AbbVie Corporation Information
Table 60. AbbVie Description and Business Overview
Table 61. AbbVie Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 62. AbbVie Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 63. AbbVie Recent Developments/Updates
Table 64. Pfizer Corporation Information
Table 65. Pfizer Description and Business Overview
Table 66. Pfizer Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 67. Pfizer Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 68. Pfizer Recent Developments/Updates
Table 69. Novartis Corporation Information
Table 70. Novartis Description and Business Overview
Table 71. Novartis Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 72. Novartis Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 73. Novartis Recent Developments/Updates
Table 74. Johnson and Johnson Corporation Information
Table 75. Johnson and Johnson Description and Business Overview
Table 76. Johnson and Johnson Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 77. Johnson and Johnson Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 78. Johnson and Johnson Recent Developments/Updates
Table 79. UCB Corporation Information
Table 80. UCB Description and Business Overview
Table 81. UCB Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 82. UCB Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 83. UCB Recent Developments/Updates
Table 84. Merck Corporation Information
Table 85. Merck Description and Business Overview
Table 86. Merck Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 87. Merck Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 88. Merck Recent Developments/Updates
Table 89. Abbott Laboratories Corporation Information
Table 90. Abbott Laboratories Description and Business Overview
Table 91. Abbott Laboratories Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 92. Abbott Laboratories Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 93. Abbott Laboratories Recent Developments/Updates
Table 94. Biogen Corporation Information
Table 95. Biogen Description and Business Overview
Table 96. Biogen Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 97. Biogen Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 98. Biogen Recent Developments/Updates
Table 99. Gilead Sciences Corporation Information
Table 100. Gilead Sciences Description and Business Overview
Table 101. Gilead Sciences Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 102. Gilead Sciences Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 103. Gilead Sciences Recent Developments/Updates
Table 104. Thermo Fisher Scientific Corporation Information
Table 105. Thermo Fisher Scientific Description and Business Overview
Table 106. Thermo Fisher Scientific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 107. Thermo Fisher Scientific Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 108. Thermo Fisher Scientific Recent Developments/Updates
Table 109. Bristol-Myers Squibb Corporation Information
Table 110. Bristol-Myers Squibb Description and Business Overview
Table 111. Bristol-Myers Squibb Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 112. Bristol-Myers Squibb Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 113. Bristol-Myers Squibb Recent Developments/Updates
Table 114. Astellas Pharma Corporation Information
Table 115. Astellas Pharma Description and Business Overview
Table 116. Astellas Pharma Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 117. Astellas Pharma Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 118. Astellas Pharma Recent Developments/Updates
Table 119. AstraZeneca Corporation Information
Table 120. AstraZeneca Description and Business Overview
Table 121. AstraZeneca Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 122. AstraZeneca Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 123. AstraZeneca Recent Developments/Updates
Table 124. Eli Lilly and Company Corporation Information
Table 125. Eli Lilly and Company Description and Business Overview
Table 126. Eli Lilly and Company Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 127. Eli Lilly and Company Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 128. Eli Lilly and Company Recent Developments/Updates
Table 129. Roche Corporation Information
Table 130. Roche Description and Business Overview
Table 131. Roche Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 132. Roche Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 133. Roche Recent Developments/Updates
Table 134. Sanofi Corporation Information
Table 135. Sanofi Description and Business Overview
Table 136. Sanofi Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 137. Sanofi Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 138. Sanofi Recent Developments/Updates
Table 139. Production Base and Market Concentration Rate of Raw Material
Table 140. Key Suppliers of Raw Materials
Table 141. Tumor Necrosis Factor (TNF) Inhibitor Drugs Distributors List
Table 142. Tumor Necrosis Factor (TNF) Inhibitor Drugs Customers List
Table 143. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Trends
Table 144. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers
Table 145. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Challenges
Table 146. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints
Table 147. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Forecast by Type (2023-2028) & (MT)
Table 148. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share Forecast by Type (2023-2028)
Table 149. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 150. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 151. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Forecast by Application (2023-2028) & (MT)
Table 152. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share Forecast by Application (2023-2028)
Table 153. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 154. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 155. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Forecast by Region (2023-2028) & (MT)
Table 156. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share Forecast by Region (2023-2028)
Table 157. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 158. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Tumor Necrosis Factor (TNF) Inhibitor Drugs
Figure 2. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type in 2021 & 2028
Figure 3. Remicade Product Picture
Figure 4. Humira Product Picture
Figure 5. Cimzia Product Picture
Figure 6. Simponi Product Picture
Figure 7. Others Product Picture
Figure 8. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application in 2021 & 2028
Figure 9. Online Pharmacies
Figure 10. Specialty Pharmacies
Figure 11. Hospital Pharmacies
Figure 12. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2017-2028) & (US$ Million)
Figure 14. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales (2017-2028) & (MT)
Figure 15. Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Share by Manufacturers in 2021
Figure 16. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Manufacturers in 2021
Figure 17. The Global 5 and 10 Largest Tumor Necrosis Factor (TNF) Inhibitor Drugs Players: Market Share by Revenue in 2021
Figure 18. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 19. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Region (2017-2022)
Figure 20. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Region in 2021
Figure 21. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region (2017-2022)
Figure 22. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region in 2021
Figure 23. U.S. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Canada Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Germany Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. France Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. U.K. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Italy Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Russia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. China Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Japan Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. South Korea Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. India Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Australia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Taiwan Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Indonesia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Thailand Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Malaysia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Philippines Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Vietnam Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Mexico Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Brazil Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Argentina Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Turkey Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Saudi Arabia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. U.A.E Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Sales Market Share of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Type (2017-2022)
Figure 48. Manufacturing Cost Structure of Tumor Necrosis Factor (TNF) Inhibitor Drugs
Figure 49. Manufacturing Process Analysis of Tumor Necrosis Factor (TNF) Inhibitor Drugs
Figure 50. Tumor Necrosis Factor (TNF) Inhibitor Drugs Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
